Xtant Medical Names Permanent CEO

Xtant Medical Holdings Inc., a developer of regenerative medicine products and medical devices, has appointed Carl O’Connell as the permanent CEO, effective February 17. O’Connell previously served as president of Xtant since October of 2016 and was appointed as interim CEO on January 21.
 
Prior to joining Xtant Medical, O’Connell most recently served as vice president of global marketing—Extremities for Wright Medical Group Inc., a major player in the global foot and ankle market. O’Connell led marketing teams and initiatives that helped the company achieve U.S. growth initiatives that exceeded 28 percent and 23 percent globally. He also lad the completion of marketing integration of three acquired businesses within a year, recruited top talent to his team, and supported the launch of multiple product line extensions and new products, including the launch of the  Infinity Total Ankle. During his tenure as global vice president of marketing for Stryker Spine, O’Connell drove marketing leadership and brand differentiation programs to support a 20 percent growth imperative, which was achieved through strategic cross divisional collaboration and the launches of line extensions and product upgrades.

O’Connell served as the president and CEO of MedSurg-ITOCHU International, a division of ITOCHU Corporation, the third-largest Japanese trading corporation with more than $70 billion in sales transactions. He was responsible for the reorganization of three recently impaired acquisitions by supporting success attributes, acquiring new vendor contracts, stabilizing and growing top line sales at double digit growth rates, and driving the division to profitability.
 
“We are proud to announce Carl O’Connell has been promoted to the position of CEO,” said Kent Swanson, Xtant Medical’s board chairman. “With his extensive leadership in the medical device industry and commercialization expertise, we are confident that he is the right choice to lead Xtant to new levels of growth and profitability. Since joining the organization as president in 2016, he has made significant contributions to the performance of the company in Q4 2016 and we share his enthusiasm for the outlook of the company.”
 
O’Connell has more than 30 years of experience in the healthcare and medical device arena. In addition to his corporate positions, O’Connell also served as a principal at Hudson Healthcare Partners, and president of Carl Zeiss Surgical Inc. O’Connell’s responsibilities have spanned from global marketing, sales, manufacturing, leadership development, regulatory affairs, corporate quality systems, research, and product and business development functions. O’Connell received a bachelor’s degree in psychology and an M.B.A. from Mount St. Mary’s College in Maryland. Throughout his career, O’Connell has launched more than 100 products and participated in numerous M&A events.

“I am excited to lead what has the potential to be a world-class organization and a considerable competitor in the market,” said O’Connell. “Since joining the organization, I have had a chance to assess the Xtant Medical team, the quality of our products, the commitment to our customers, the respect for the gift of donation, and the opportunity that lies ahead. I look forward to continuing to work with this team, expanding upon our recent successes and continuing to establish the strategic course to take Xtant Medical to the next level.  I am appreciative of the confidence bestowed in me by the executive management team, the board of directors, and our stakeholders.”
 
Xtant Medical develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant Medical products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant Medical can leverage its resources to successfully compete in global neurological and orthopedic surgery markets.